Skip to main content
. 2016 Jun 13;29(6):832–845. doi: 10.1016/j.ccell.2016.04.014

Figure 3.

Figure 3

Cxcr2 Deletion Inhibits Metastasis in KPC Mice

(A) Kaplan-Meier survival analysis of KPC and KPC Cxcr2−/− mice untreated, or treated from 10 weeks of age with 100 mg/kg gemcitabine, n = 21, 24, 10, 13, respectively (not significant, log rank test).

(B) Table comparing incidence of metastases in KPC and KPC Cxcr2−/− mice treated as indicated. p Values, chi-square test.

(C and D) H&E staining of representative primary tumors from (C) KPC and (D) KPC Cxcr2−/− mice.

(E and F) H&E staining of representative (E) liver and (F) diaphragm metastasis from KPC mice.

(G and H) IHC for MPO, F4/80, CD3, and tenascin C (TNC) in tumors from (G) KPC and (H) KPC Cxcr2−/− mice.

(I and J) Boxplots of signature scores (I) upregulated and (J) downregulated, in KPC Cxcr2−/− mice, stratified by human PDAC class. p Values, Kruskall-Wallis test. See also Figure S3.